Trial Profile
Examination of the effect by taking the sodium glucose transporter 2 inhibitor everyday or only when a patient thinks it to be necessary for type 2 diabetes patients controlled inadequately.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 11 Oct 2022 Status changed from active, no longer recruiting to completed.
- 12 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Oct 2015 New trial record